Downregulation of FOXD3 levels by promoter methylation in colon cancer might provide a favorable setting for either acquisition of a BRAF mutation or proliferation by RAS-RAF-MEK over-activation, similar to IGFBP7[2]. Here, BRAF is linked to malignant colon neoplasm.